Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

Author： Kontoghiorghes G J   Kolnagou A   Peng C-T   Shah S V   Aessopos A  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.9, Iss.2, 2010-03, pp. : 201-206

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of Iron Chelation in Cancer Therapy

By  

Current Medicinal Chemistry, Vol. 10, Iss. 12, 2003-06 ,pp. : 1021-1034

Bentham Science Publishers

Access to resources Recommend Favorite

Erythropoietin and iron therapy in patients with renal failure

By DEL VECCHIO LUCIA   LOCATELLI FRANCESCO  

Transfusion Alternatives in Transfusion Medicine, Vol. 11, Iss. 1, 2010-03 ,pp. : 20-29

Blackwell Publishing

Access to resources Recommend Favorite

ICL 670: effective oral iron chelation therapy

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3222-3234

Bentham Science Publishers

Access to resources Recommend Favorite

Use chelation therapy to reduce iron overload and improve survival in patients with myelodysplastic syndromes

By  

Drugs & Therapy Perspectives, Vol. 27, Iss. 9, 2011-09 ,pp. : 14-17

Adis International

Access to resources Recommend Favorite